Shares of MiMedx Group Inc. MDXG, -34.73% plummeted 34% to pace all Nasdaq losers in morning trade Wednesday, after the biopharmaceutical company disclosed that the Nasdaq will suspend trading in its stock starting Nov. 8, ahead of a delisting. The delisting notice comes as the company has failed to regain compliance with Securities and Exchange Commission reporting obligations amid an internal accounting investigation. Separately, the company said it has adopted a shareholder rights plan, also known as a “poison pill,” that becomes exercisable of an investor acquires ownership of 10% or more of MiMedx common stock, in an effort to block an unsolicited buyout attempt. The stock has now lost 67% year to date, while the iShares Nasdaq Biotechnology ETF IBB, +0.82% has gained 2.4% and the S&P 500 SPX, +0.81% has advanced 3.9%.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.